IBSA has developed a full line of NSAIDs presentations based on its proprietary patented epolamine (EP)salt of diclofenac. EP diclofenac enjoys enhanced solubility in both acqueous and lipidic compartments, which render it a perfect molecule for transdermal delivery.

Please find here below the available licensing opportunities.

Description
Adhesive plasters containing 180 mg of diclofenac epolamine. The active substance in dissolved in 14 grams of hydrogel ensuring the sustained release for 12-24 hours.

Indication
For the symptomatic relief of rheumatic pain, lumbago and muscular aches, pains and swellings such as strains, sprains and sports injuries.

Status
Approved and marketed in the majority of the EU countries (MRP) as well as in many non-EU countries. According to the country, the product may be approved as ethical or as OTC.

Claims
Effective transdermal delivery without systemic side effects. Clean and practical, avoids the need for occlusive bandages. Very first available NSAID plaster, it is market leader in many countries.

Countries available for licensing
Available on semi-exclusive basis for UK.

For details see Page Extensions

For information please contact: